For this purpose, we established a novel triple transgenic AD mouse model (Ttg) carrying the Swedish mutation (APP23) together with conditional neuroinflammation, restricted to astrocytes (GFAP.tTA/tetO.IKK2-CA), in order to dissect the consequences of the astrocyte-driven inflammatory response on microglial cells and AD plaque pathology. The gene discussed is GFAP; the disease is Alzheimer disease.